BioPharmSignal logoBioPharmSignal

Biotech News

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Prelude Therapeutics (PRLD)Prelude TherapeuticsEarnings

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development and IND

Related news

PRLDPrelude Therapeutics2026-08-11 11:00 EST

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

View all latest news

Prelude Therapeutics

Precision Oncology Company Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition. PRT12396 PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis. PRT13722 PRT13722 is an oral KAT6A degrader intended for...

Recent company news

PRLDPrelude Therapeutics2026-08-11 11:00 EST

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRLDPrelude Therapeutics2026-05-12 11:01 EST

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

PRLDPrelude Therapeutics2026-04-20 10:30 EST

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

PRLDPrelude Therapeutics2026-04-20 10:00 EST

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

PRLDPrelude Therapeutics2026-04-15 11:30 EST

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

Stock data

Close
6.63 USD
Market cap
278.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States